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Purpose: As part of the approval process, regulatory
authorities often require postauthorization studies that
involve patient registries; it is unknown, however,
whether such registry studies are adequately completed.
We investigated whether registry studies for new drugs
were performed as agreed at time of approval.
Methods: This study reviewed protocols and follow-up
reports for 73 registry studies that were proposed for 43
drugs approved by the Committee for Medicinal Products
for Human Use in Europe in the period 2007 to 2010.
Results: The data lock point of January 1, 2016,
was taken to allow a 5-year follow-up period for each
drug after approval. At that time, 2 studies (3%) in
registries had been ﬁnalized, 19 registries (26%) had not
enrolled any patients, and 52 studies (71%) were
ongoing. The median enrollment was 31% (interquar-
tile range [IQR], 6–104) of the required number of
patients for 41 registry studies that had a predeﬁned
sample size, 30% (IQR, 2–101) for nonimposed regis-
tries, and 61% (IQR, 18–144) for imposed registries.
Implications: Enrollment of patients into postap-
proval registries is poor, although the results for
imposed registries seem better. Currently, registries only
have a limited impact on resolving gaps in the knowl-
edge of a drug’s beneﬁts and risks at time of marketing
authorization. (Clin Ther. 2018;40:768–773) & 2018
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Approval is a discrete moment in the life cycle of a
drug, after which the drug typically becomes widely768available to the public. However, full knowledge
regarding the drug’s beneﬁts and risks is not complete
at this point. For some drugs, regulators and industry
may agree on collecting further clinical data through
additional trials or observational studies. There is a
trend to expand the collection of clinical research data
into more “real-life” data settings such as patient or
drug registries. Registries, or registry studies, may be
deemed necessary if, at the time of approval, the
beneﬁts, but especially the risks, are not completely
understood. Registries may be either newly developed
as a consequence of a decision by the regulatory
agency (eg, European Medicines Agency [EMA]) as
a “new registry” or “registry studies” can be per-
formed in existing disease registries or other data-
bases. Regulators may even impose a registry as a
speciﬁc obligation to address a particular concern
with respect to either safety or efﬁcacy, in the frame-
work of the marketing authorization. Moreover, the
EMA has proposed in its adaptive pathways project to
use registry data to generate postapproval data in
more extended patient populations while giving an
early license in a restricted population.1 However,
some criticism was raised with respect to this option
because it is considered that industry does not always
fulﬁll its postapproval commitments in a timely
fashion.2–4 The most recent review of postapproval
studies agreed with the US Food and Drug Admin-
istration, which showed that 5 to 6 years afterVolume 40 Number 5
C.J. Jonker et al.approval, 20% of these studies had not started patient
inclusion, 25% were delayed or ongoing, and only
54% had been completed.5
Evidence is lacking from Europe whether it is
realistic to expect that this kind of early approval
(with “real-world” registry data being provided post-
approval) is effective. Therefore, we reviewed for
drugs approved between 2007 and 2010 by the
Committee for Medicinal Products for Human Use
in Europe. We previously reported that for 43 (37%)
of 116 drugs approved in this period, 73 studies in
registries had been proposed.6 The present study
investigated if the planned number of patients had
been enrolled, the results are made publically
available, and if the registry studies provided
evidence that affected the known beneﬁt–risk balance.MATERIALS AND METHODS
The European Public Assessment Reports (EPAR),
which are publicly available via the EMA website
(http://www.ema.europa.eu/ema/), were investigated
for scientiﬁc and regulatory information of the 43
drugs that had been approved in Europe by the
Committee for Medicinal Products for Human Use
between 2007 and 2010 and where a commitment
was made to perform at least 1 study in a registry. The
2007 to 2010 time period was chosen to allow at least
a 5-year follow-up for each drug after approval. This
approach is in line with the time for submitting a
renewal application (ie, the obligatory re-evaluation
after 5 years of the risk–beneﬁt balance of any new
medicinal product after its initial approval).7 The lead
author (C.J.J.) reviewed the statistical analysis plan of
the registry study protocol to determine whether
target enrollment was achieved. The Mann-Whitney
U test was used to test if enrollment differed between
imposed and nonimposed registries and between
disease and product registries. In addition, we
evaluated what impact the data had on the drug’s
beneﬁt–risk balance (ie, a change in the product label)
after 5 years. To this end, EPAR updates were
reviewed by using the term “registry” or the name
of the registry or registry study to ﬁnd evidence that
these data were mentioned in the EPAR irrespective of
whether they led to updates of the drug labeling. All
data were systematically checked by 2 of the authors
(P.G.M.M. or M.S.G.K.) to ensure accuracy of
extracted information. Any discrepancies wereMay 2018resolved in discussion with 3 of the authors (C.J.J.,
M.S.G.K., and P.G.M.M.).
PubMed was searched to determine if the protocols
or ﬁndings of the registry or registry studies had been
published in a peer-reviewed journal to investigate if
translation of knowledge had occurred from registry
owners and industry to health care professionals and
the scientiﬁc community. Search terms included the
generic name of the drug and the term “registry” or
the name of the registry or study as recorded in the
EPAR. The status of the registry with respect to
statistical analysis plan and enrollment was retrieved
from the study reports submitted to the Dutch
Medicines Evaluation Board; the data lock point
was January 1, 2016.RESULTS
Of the 73 identiﬁed registry studies, 9 (12%) were
imposed by the regulatory authority as a speciﬁc
postapproval obligation.6 The remaining 64
registries were proposed voluntarily by companies
and agreed with by the regulatory authority. At the
data lock point of January 1, 2016, two registry
studies (3%) had been ﬁnalized,8 and 52 studies
(71%) were ongoing. In 19 registries (26%), no
patients were enrolled. Reasons for not enrolling any
patients were as follows: withdrawal of the drug from
the market (4 [of which 2 registry studies had been
imposed]), the drug was not reimbursed (1), the data
were collected through other pharmacovigilance
activities (2), and there was no (recorded) use of the
drug in the at risk population (pregnant women) (3).
For 9 registries, the reason could not be retrieved from
the data submitted to the agency.
The planned number of patients to be included was
described in the statistical analysis plan of 41 registry
studies (56%); for the imposed registry studies, this
factor was known for 7 (78%) of 9 registry studies.
The Figure shows the percentage of patients enrolled
in registry studies with a predeﬁned number of
patients to-be-enrolled in the statistical analysis plan.
The median enrollment in these 41 registry studies
was 31% (interquartile range [IQR], 6–104) of the
required sample size, 30% (IQR, 2–101) for
nonimposed registries, and 61% (IQR, 18–144) for
imposed registries (P ¼ 0.46). The median enrollment
in product registries was 50% (IQR, 1–119) and 28%
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Figure. Percentage of patients enrolled in registry studies with a predefined number of patients to-be-enrolled
in the statistical analysis plan. The bars indicate the percentage of patients enrolled from those
planned to-be-enrolled in registry studies (data lock point is January 1, 2016). The green bars indicate
the disease registries, the blue bars the product registries, and the striped bars the registries that were
imposed. Note that for 32 registries, the percentage could not be calculated due to missing numbers.
Clinical TherapeuticsFor 6 drugs, data from the registry studies were
published in a follow-up EPAR published on the EMA
website.9–14 In addition, for 2 products, these data led to
changes in the Summary of Product Characteristics (ie,
the drug label). The ﬁrst drug is eculizumab; at the time
of approval, a single pivotal study supported the
beneﬁt–risk of eculizumab in patients with paroxysmal
nocturnal hemoglobinuria but only in patients who
had undergone transfusion previously.9 The registry
study data then conﬁrmed that a positive beneﬁt–risk
applied to all patients with paroxysmal nocturnal
hemoglobinuria irrespective whether they had a
previous transfusion. The second drug that led to a
label change was the inﬂuenza A (H1N1) pandemic
vaccine, for which the results of the registry study
conducted in pregnant women (an important hitherto
not studied population) showed that the vaccine was not
associated with an increased risk of adverse pregnancy
outcomes.10 The 4 other registry studies reported in
EPARs complemented the limited datasets at time of
approval conﬁrming the beneﬁt–risk balance at this time
point, thus not requiring any label changes. Two
registries—Psoriasis Longitudinal Assessment Registry770and the Icatibant Outcome Survey) for ustekinumab and
icatibant, respectively—provided reassurance that no
new safety signals emerged.11,12 Registry data indicated
that longer treatment of romiplostim did not lead to
unexpected immunogencity.13 Finally, the US Cystic
Fibrosis Foundation Patient Registry provided
controlled long-term effectiveness data for aztreonam
lysine; it reported a better outcome of aztreonam-treated
patients with respect to hospitalization.14
Data from 11 registry studies (15%) were pub-
lished in peer-reviewed journals.8,15–24 For 4 registry
studies, these data were only published for the base-
line characteristics of the patients enrolled15,16 and/or
the enrollment process was described.17,18 Five articles
published baseline data and interim data after 1 year19
or after ≥1 years of treatment.20–23 Publications with
data generated in a registry of pregnant women
receiving the pandemic vaccine provided evidence on
absence of risk, which (as described earlier) is also
reﬂected in the Summary of Product Characteristics.8
Data from pregnant women with Gaucher disease
suggest that continuing treatment during pregnancy
may be appropriate.24Volume 40 Number 5
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The present study, including 73 postapproval studies in
registries imposed or agreed on by the Committee for
Medicinal Products for Human Use, showed that 5 years
after approval, only 2 registry studies (3%) had been
ﬁnalized8 and that 19 registries (26%) had not enrolled
any patients. Of the 41 registry studies with predeﬁned
sample sizes, enrollment was poor (median inclusion of
31% for all registry studies), albeit that inclusion for
imposed registry studies seemed better (61% vs 30%
enrollment for nonimposed registry studies).
In 2012, pharmacovigilance legislation was imple-
mented to enable regulators to protect the public from
emerging safety issues not only at the time of approval
of a drug but throughout a drug's life cycle. The
impact on industry is that a clear legal framework for
postauthorization monitoring has been established.
Regulators can now take action if industry does not
complete its postapproval studies.25 Our study was
performed on drugs approved before the new
pharmacovigilance legislation came into force. This
approach was taken to allow registries to mature,
considering among others the delay in “real-world”
use of a drug after approval due to sometimes
protracted reimbursement negotiations. Obviously,
we cannot dismiss the possibility that the new
pharmacovigilance regulation may have had an
impact on the performance of registries. Two studies
focusing on more recent imposed registry studies
(albeit with inherently shorter follow-up periods
than our study and one being a study from the
United States) however, found similar results of slow
recruitment.26,27 What we add is that even with longer
follow-up periods, recruitment in registries remains
poor and that imposed registry studies (a regulatory
tool that is likely to have been used more frequently
since the new pharmacovigilance legislation) may
perform better than nonimposed ones. The exact
reasons for poor recruitment were not easily identiﬁ-
able in our study. For 9 registries, no reason was
provided for the lack of or poor enrollment. To
improve enrollment for the future, more attention is
needed on the feasibility to conduct a registry; for
example, whether an existing registry is available. It is
important that this factor has been explored by both
industry and the regulatory authority beforehand.28
Finally, EMA promotes making use of existing
disease registries.28 These registries have the
advantage of having already shown the ability toMay 2018recruit and follow up patients. These registries
usually have extensive track records of generated
valuable health care knowledge beyond speciﬁc
effects of a drug of interest, and they may provide
historical or contemporaneous control data. Product
registries, conversely, may have the advantage that
industry sponsors pay data monitors to ensure quality
and validity of data entered into the registry. In
contrast, disease registries are often created by
academic investigators, where quality control may be
limited due to limited resources. These differences may
affect accrual rates and success of the studies
performed in registries. Interestingly, data from our
study suggested, however, that product registries
achieved higher enrollment rates.
Our study also showed that for a few drugs only, the
data generated from registries were published on the
EMA website or in peer-reviewed journals. Only 8 of
the 73 registry studies reviewed in the present study
were published in the European Union electronic Regis-
ter of Post-Authorisation Studies, but it should be kept
in mind that this register was launched in November
2010, whereas our study period was 2006 to 2010.
Once a drug is approved, it will usually be used by
much larger numbers of patients than studied pre-
approval. Safety and/or efﬁcacy data generated in the
registry or real-world setting can only translate into
knowledge for prescribers and other health care
professionals if such data are made publicly avail-
able. Although it is challenging to study the exact
impact of registry data on the knowledge of beneﬁts
and risks of any drug, the knowledge obtained thus
far through registries seems limited. Results of
6 registries were mentioned in EPAR updates only,
of which 2 (eculizumab and inﬂuenza A [H1N1]
pandemic vaccine) resulted in changes in the label.
A small proportion of the registry studies were
published in the peer review literature. Our results
on poor performance of registry studies ties in with
the work of Vermeer et al,29 who found that only one
ﬁfth of all uncertainties described in Risk
Management Plans were resolved 5 years after
marketing authorization. Importantly, Hoekman
et al30 showed that most postmarketing obligations
were eventually completed but often with substantial
delay. We appreciate the work done so far by
regulators to be more transparent31 and to swiftly
publish information on their developing knowledge
of the beneﬁts and risks of drugs. Our results771
Clinical Therapeuticssuggest, however, that more effort is needed from all
stakeholders.
Poor performance of postapproval registry studies
challenges the real-world evaluation of, for example,
rare cancer drugs that require further data to comple-
ment the knowledge on drug beneﬁts and harms after
approval. To improve the knowledge of new drugs, the
value of registries depends not only on recruitment but
also on quality and completeness of the data collected;
some articles suggest that improvements need to be
made in this context as well.32,33 Although postap-
proval registries are, however, just one part of the real-
world evaluation, the poor performance of studies in
these registries challenges the authorization of drugs.
This situation can only be improved if regulators are
explicit about data that are needed and what the
consequences will be if data are not timely delivered.CONCLUSIONS
Five years after approval, only 2 (3%) of 73 registry
studies had been ﬁnalized, 19 registries (26%) had not
enrolled any patients, and 52 (71%) were ongoing.
Enrollment for imposed registries seemed better, but
the overall inclusion rate was poor. Registries have
had only a limited impact on resolving gaps in the
knowledge of a drug’s beneﬁts and risks at the time of
marketing authorization. It is important to be careful
with broadening the use of postmarketing studies as a
means of resolving uncertainties about beneﬁts and
risks after marketing authorization.30ACKNOWLEDGMENTS
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